Astrazeneca (AZN) Total Current Liabilities (2009 - 2026)
Astrazeneca (AZN) posted quarterly Total Current Liabilities of $31.6 billion for Q2 2026, down 5.91% year-over-year from $33.5 billion in Q2 2025, and up 196.88% quarter-over-quarter from -$32.6 billion in Q1 2026.
Astrazeneca (AZN) Total Current Liabilities (2009 - 2026) Analysis & Trends
Astrazeneca's Total Current Liabilities history runs 18 years deep, the most recent figure standing at $31.6 billion for Q2 2026.
- In Q2 2026, Total Current Liabilities fell 5.91% year-over-year to $31.6 billion; the TTM figure through Jun 2026 stood at $31.6 billion (down 5.91% YoY), while the FY2025 annual figure was $30.6 billion, up 9.87% from the prior year.
- Total Current Liabilities for Q2 2026 stood at $31.6 billion, up from -$32.6 billion in the prior quarter.
- The five-year high for Total Current Liabilities was $33.5 billion in Q2 2025, with the low at -$34.1 billion in Q3 2025.
- The 5-year median for Total Current Liabilities is -$24.9 billion (2022), against an average of -$8.2 billion.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities plunged 33.79% in 2022, then surged 217.4% in 2025.
- Astrazeneca's Total Current Liabilities stood at $26.3 billion in 2022, then gained by 16.16% to $30.5 billion in 2023, then dropped by 8.76% to $27.9 billion in 2024, then grew by 9.87% to $30.6 billion in 2025, then advanced by 3.06% to $31.6 billion in 2026.
- Business Quant data shows AZN's Total Current Liabilities at $31.6 billion in Q2 2026, -$32.6 billion in Q1 2026, and $30.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.66 Bn | 631.90 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 469.44 Bn | 462.87 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 377.01 Bn | 369.86 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 302.49 Bn | 294.80 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Astrazeneca | 257.82 Bn | 252.92 Bn | 12.86 Bn | 31.55 Bn |
| 6 | Amgen | 236.92 Bn | 222.93 Bn | 7.24 Bn | 25.50 Bn |
| 7 | Gilead Sciences | 183.04 Bn | 179.87 Bn | 6.22 Bn | 11.02 Bn |
| 8 | Pfizer | 160.40 Bn | 148.70 Bn | 10.94 Bn | 32.65 Bn |
| 9 | Gsk | 106.00 Bn | 101.84 Bn | 8.24 Bn | -28.89 Bn |
| 10 | Sanofi | 55.28 Bn | 47.90 Bn | 10.79 Bn | 37.11 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.55 Bn |
| Mar 31, 2026 | -32.57 Bn |
| Dec 31, 2025 | 30.62 Bn |
| Sep 30, 2025 | -34.05 Bn |
| Jun 30, 2025 | 33.54 Bn |
| Mar 31, 2025 | -29.13 Bn |
| Dec 31, 2024 | 27.87 Bn |
| Sep 30, 2024 | -25.93 Bn |
| Jun 30, 2024 | -28.57 Bn |
| Mar 31, 2024 | -28.90 Bn |
| Dec 31, 2023 | 30.54 Bn |
| Sep 30, 2023 | -28.59 Bn |
| Jun 30, 2023 | -26.38 Bn |
| Mar 31, 2023 | -24.86 Bn |
| Dec 31, 2022 | 26.29 Bn |
| Sep 30, 2022 | -24.85 Bn |
| Jun 30, 2022 | -21.82 Bn |
| Mar 31, 2022 | -22.74 Bn |
| Dec 31, 2021 | 22.59 Bn |
| Sep 30, 2021 | -23.65 Bn |